Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LARA: Lenvatinib + Pembrolizumab in Recurrent Gynecological Clear Cell Adenocarcinomas
NCT04699071Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Feb 2021
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and pembrolizumab in clear cell carcinoma (CCC), sponsored by National University Hospital. Primary endpoint: Objective Response Rate at 24 weeks. Status: unknown.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
clear cell carcinoma (CCC)
Beyond the preview
Go deeper on NCT04699071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699071.